WallStreetZenWallStreetZen

NASDAQ: SEEL
Seelos Therapeutics Inc Stock

$1.33-0.04 (-2.92%)
Updated May 24, 2024
SEEL Price
$1.33
Fair Value Price
N/A
Market Cap
$2.89M
52 Week Low
$1.30
52 Week High
$398.40
P/E
-0.04x
P/B
-0.09x
P/S
3.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.97M
Earnings
-$27.12M
Gross Margin
100%
Operating Margin
-1,369%
Profit Margin
-1,373.6%
Debt to Equity
-1.11
Operating Cash Flow
-$18M
Beta
1.16
Next Earnings
May 30, 2024
Ex-Dividend
N/A
Next Dividend
N/A

SEEL Overview

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SEEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SEEL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SEEL is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
SEEL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more SEEL due diligence checks available for Premium users.

Be the first to know about important SEEL news, forecast changes, insider trades & much more!

SEEL News

Valuation

SEEL fair value

Fair Value of SEEL stock based on Discounted Cash Flow (DCF)
Price
$1.33
Fair Value
-$1.88
Undervalued by
170.57%
SEEL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SEEL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.04x
Industry
15.58x
Market
32.03x

SEEL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.09x
Industry
6.08x

SEEL's financial health

Profit margin

Revenue
$579.0k
Net Income
-$2.7M
Profit Margin
-460.1%
SEEL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SEEL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$3.6M
Liabilities
$36.7M
Debt to equity
-1.11
SEEL's short-term liabilities ($36.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SEEL's short-term assets ($3.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SEEL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SEEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.6M
Investing
$0.0
Financing
$2.2M
SEEL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SEEL vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SEEL$2.89M-2.92%-0.04x-0.09x
FNCH$2.89M-9.09%-0.18x0.15x
APVO$2.90M-2.60%-0.01x0.48x
XCUR$2.85M-26.34%0.16x0.63x
QNRX$2.95M+2.78%N/A0.32x

Seelos Therapeutics Stock FAQ

What is Seelos Therapeutics's quote symbol?

(NASDAQ: SEEL) Seelos Therapeutics trades on the NASDAQ under the ticker symbol SEEL. Seelos Therapeutics stock quotes can also be displayed as NASDAQ: SEEL.

If you're new to stock investing, here's how to buy Seelos Therapeutics stock.

What is the 52 week high and low for Seelos Therapeutics (NASDAQ: SEEL)?

(NASDAQ: SEEL) Seelos Therapeutics's 52-week high was $398.40, and its 52-week low was $1.30. It is currently -99.67% from its 52-week high and 2.31% from its 52-week low.

How much is Seelos Therapeutics stock worth today?

(NASDAQ: SEEL) Seelos Therapeutics currently has 2,173,080 outstanding shares. With Seelos Therapeutics stock trading at $1.33 per share, the total value of Seelos Therapeutics stock (market capitalization) is $2.89M.

Seelos Therapeutics stock was originally listed at a price of $2,160,002.16 in Apr 19, 1999. If you had invested in Seelos Therapeutics stock at $2,160,002.16, your return over the last 25 years would have been -100%, for an annualized return of -43.56% (not including any dividends or dividend reinvestments).

How much is Seelos Therapeutics's stock price per share?

(NASDAQ: SEEL) Seelos Therapeutics stock price per share is $1.33 today (as of May 24, 2024).

What is Seelos Therapeutics's Market Cap?

(NASDAQ: SEEL) Seelos Therapeutics's market cap is $2.89M, as of May 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Seelos Therapeutics's market cap is calculated by multiplying SEEL's current stock price of $1.33 by SEEL's total outstanding shares of 2,173,080.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.